Shidong Jia, MD, PhD, is the Founder and CEO of Predicine. Prior to founding Predicine, Shidong spearheaded the oncology biomarker strategies and drug & diagnostics co-development at Genentech. His previous work identified p110beta as novel drug target for PTEN-deficient tumors, a finding that laid the foundation for clinical development and testing of p110beta inhibitors in cancers. He previously held various senior research positions focusing on translational and clinical cancer research at Novartis Institutes for BioMedical Research and Harvard University. Shidong was awarded the P.A.R.T. Investigatorship Award from the Dana-Farber Cancer Institute. Shidong holds a MD and PhD from Harbin Medical University and Peking Union Medical College, and completed postdoctoral training at the Dana-Farber Cancer Institute – Harvard University.

Pan Du, PhD, is the Co-founder, President and CTO at Predicine. Pan is an expert in next-generation sequencing, bioinformatics, and oncology diagnostics. He has developed multiple widely used bioinformatics analysis software and has authored numerous publications, including several 1st authorship manuscripts that are cited over thousands times. Prior to Predicine, Pan was Principal Scientist at Roche Diagnostics and Senior Computational Biologist at Genentech. He was previously an Assistant Professor at Biomedical Informatics Center at Northwestern University. Pan holds a PhD with distinction in both Bioinformatics and Electrical Engineering from Iowa State University.